News & Events

In her role as study principal investigator, Laura Mauri, M.D., M.S. will present a DAPT Study update at the 2009 TCT Conference on Monday September 21 at 2:33 PM Pacific.  The DAPT Study is an independent, large-scale study in size and scope intended to determine the appropriate duration for dual antiplatelet therapy to protect patients from stent thrombosis and major adverse cardiovascular and cerebrovascular events (MACCE) following the implantation of drug-eluting coronary stents.  Following a December 2006 Advisory Panel, the FDA requested that drug-eluting stent (DES) manufacturers support a study to define the optimal duration of dual antiplatelet therapy for DES safety.  This request resulted in a unique public-private collaboration among a group of 8 manufacturers of stent and antiplatelet medications, the FDA and Harvard Clinical Research Institute.  HCRI is the sponsor of the IDE study and is responsible for the scientific conduct of the DAPT Study and independent analysis of the resulting data.  More information will be coming soon at www.DAPTStudy.org.